Cargando…

SARS-CoV-2 Y453F is not the “cluster 5” variant

Detalles Bibliográficos
Autor principal:	Lassaunière, Ria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Biochemistry and Molecular Biology 2021
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8541821/ https://www.ncbi.nlm.nih.gov/pubmed/34700073 http://dx.doi.org/10.1016/j.jbc.2021.101242

Ejemplares similares

Reply to Lassaunière: On the functional characterization of the Y453F RBD variant found in cluster 5 SARS-CoV-2
por: Bayarri-Olmos, Rafael, et al.
Publicado: (2021)

SARS-CoV-2 vaccine-induced antibody levels: what lies beneath
por: Lassaunière, Ria, et al.
Publicado: (2022)

The SARS-CoV-2 Y453F mink variant displays a pronounced increase in ACE-2 affinity but does not challenge antibody neutralization
por: Bayarri-Olmos, Rafael, et al.
Publicado: (2021)

Neutralizing Antibodies Against the SARS-CoV-2 Omicron Variant (BA.1) 1 to 18 Weeks After the Second and Third Doses of the BNT162b2 mRNA Vaccine
por: Lassaunière, Ria, et al.
Publicado: (2022)

Introduction of the South African SARS-CoV-2 variant 501Y.V2 into the UK
por: Tang, Julian W., et al.
Publicado: (2021)

The basis of a more contagious 501Y.V1 variant of SARS-CoV-2
por: Liu, Haolin, et al.
Publicado: (2021)

453. Neutralizing Antibody Responses to SARS-CoV-2 in Professional Soccer Players
por: Pagura, Jorge, et al.
Publicado: (2021)

Mutation Y453F in the spike protein of SARS-CoV-2 enhances interaction with the mink ACE2 receptor for host adaption
por: Ren, Wenlin, et al.
Publicado: (2021)

Preliminary data on severe SARS-CoV-2 infection caused by the 501Y.V2 variant
por: Louis, Guillaume, et al.
Publicado: (2021)

Omicron variant in the current SARS-CoV-2 pandemic
por: Nasiri, Kaveh, et al.
Publicado: (2022)

The study of olfactory dysfunction in SARS-CoV-2 variants
por: Vaira, Luigi A., et al.
Publicado: (2022)

SARS-CoV-2 variant-dependent inflammasome activation
por: Teyssou, Elisa, et al.
Publicado: (2023)

Determinants of reinfection with SARS-CoV-2 Omicron variant
por: Bisharat, N., et al.
Publicado: (2023)

5-Aminolevulinic acid antiviral efficacy against SARS-CoV-2 omicron variant in vitro
por: Ngwe Tun, Mya Myat, et al.
Publicado: (2022)

Two SARS-CoV-2 serology assays detect antibodies in the sera of individuals diagnosed with SARS-CoV-2 Omicron variant
por: Conklin, Justin, et al.
Publicado: (2022)

Detecting spread of SARS‐CoV‐2 variants using PowerChek SARS‐CoV‐2 S‐gene mutation detection kit
por: Kim, Hyun Jin, et al.
Publicado: (2022)

Different SARS-CoV-2 variants, same prevention strategies
por: Dzinamarira, Tafadzwa, et al.
Publicado: (2021)

High rate of reinfection with the SARS-CoV-2 Omicron variant
por: Nguyen, Nhu Ngoc, et al.
Publicado: (2022)

Emergence of a new SARS-CoV-2 variant in the UK
por: Tang, Julian W, et al.
Publicado: (2021)

What Is New With Omicron Variant of SARS-CoV-2 in Children?
por: Bittmann, Stefan, et al.
Publicado: (2022)

SARS‐CoV‐2 omicron variant: Could it be another threat?
por: Shanmugaraj, Balamurugan, et al.
Publicado: (2022)

Risk factors for SARS-CoV-2 transmission in non-household clusters
por: Noh, Ji Yun, et al.
Publicado: (2021)

Household clustering of SARS-CoV-2 variant of concern B.1.1.7 (VOC-202012–01) in England
por: Chudasama, Dimple Y., et al.
Publicado: (2021)

453. Frequency of Symptoms and Asymptomatic SARS-CoV-2 Infection in New Orleans, Louisiana
por: Feehan, Amy K, et al.
Publicado: (2020)

In vitro Characterization of Fitness and Convalescent Antibody Neutralization of SARS-CoV-2 Cluster 5 Variant Emerging in Mink at Danish Farms
por: Lassaunière, Ria, et al.
Publicado: (2021)

Inhaled heparin polysaccharide nanodecoy against SARS-CoV-2 and variants
por: Tu, Bin, et al.
Publicado: (2022)

Highly efficient respirators are needed for the Omicron variant of SARS-CoV-2
por: Mattiuzzi, C., et al.
Publicado: (2022)

Does SARS-CoV-2 re-infection depend on virus variant?
por: Gautret, Philippe, et al.
Publicado: (2021)

Is diffusion of SARS-CoV-2 variants of concern associated with different symptoms?
por: Mattiuzzi, Camilla, et al.
Publicado: (2022)

Covid-19 convalescent plasma and SARS-CoV-2 viral variants
por: Joob, B., et al.
Publicado: (2021)

Multivalent vaccines against new SARS-CoV-2 hybrid variants
por: Ghazvini, Kiarash, et al.
Publicado: (2023)

Detection of SARS-CoV-2 by Use of the Cepheid Xpert Xpress SARS-CoV-2 and Roche cobas SARS-CoV-2 Assays
por: Moran, Angelica, et al.
Publicado: (2020)

Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant
por: Xia, Shuai, et al.
Publicado: (2022)

453. Distribution of cycle threshold values and the associated factors of SARS-CoV-2 omicron variant in a community setting in Japan
por: Mutoh, Yoshikazu, et al.
Publicado: (2023)

Introduction of Brazilian SARS-CoV-2 484K.V2 related variants into the UK
por: Toovey, Oliver T.R., et al.
Publicado: (2021)

The dynamics of antibodies to SARS-CoV-2 in a case of SARS-CoV-2 infection
por: Xia, Yong, et al.
Publicado: (2020)

The Emergence of Sars-CoV-2 Variant Lambda (C.37) in South America
por: Romero, Pedro E., et al.
Publicado: (2021)

SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination
por: Li, Pengfei, et al.
Publicado: (2022)

Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimab
por: Vellas, Camille, et al.
Publicado: (2022)

Synergism of interferon-beta with antiviral drugs against SARS-CoV-2 variants
por: Bojkova, Denisa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a7srkj98r52p1fjdhe16flf238